Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-11-30

FDA Approved: CONTRAVE EXTENDED-RELEASE — Supplemental Application (Nalpropion Pharmaceuticals LLC)

View source ↗

Summary

FDA approved a supplemental application to authorize an extended-release formulation of CONTRAVE (naltrexone hydrochloride and bupropion hydrochloride) for weig…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CONTRAVE EXTENDED-RELEASE (Naltrexone hydrochloride and bupropion hydrochloride)

Snippet

SUPPL AP for CONTRAVE EXTENDED-RELEASE (NALTREXONE HYDROCHLORIDE AND BUPROPION HYDROCHLORIDE)